CD1D and Miyoshi myopathy: To assess the antitumor capacity of AlloBCAR-iNKT cells, we used an established in vitro MM.1S-CD1d-FG tumor cell killing assay28; non-CAR-engineered AlloHSC-iNKT cells, as well as healthy donor PBMC-derived conventional T cells with or without engineering with the same BCAR (denoted as PBMC-T or BCAR-T cells), were included as controls (Figure 4C).